Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerEur. J. Cancer 2023 May 01;184(xx)39-47, ME Robson, SA Im, E Senkus, B Xu, SM Domchek, N Masuda, S Delaloge, N Tung, A Armstrong, M Dymond, A Fielding, A Allen, P Conte
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.